Replies to post #27417 on Humanigen Inc (HGENQ)

[CJames22]

It leaves a bit of a sour taste for sure... thinking about the risk I took pre-P3 release only to see the price where it is today.

But I'm taking full advantage of this opportunity. Sub-20 at this point seems like an incredible discount right now. I've almost doubled my position and expect the price to ramp up quickly once this offering is closed

[Gustyhu]

And yea, I have owned other companies that made that crystal clear from the jump. Semantics aside. But they need folks other than scientists handling this stuff. First move I've really disagreed with from these guys, amateur move on their part knowing how many long term retail holders they have.
Note to management: get a money guy on board ASAP...

[Corundum]

Not sure where they failed. Their Press Release stated:

BURLINGAME, Calif.--(BUSINESS WIRE)-- Humanigen, Inc. (Nasdaq:HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called “cytokine storm” with its lead drug candidate lenzilumab™, today announced that it has priced its underwritten public offering of 5,000,000 shares of its common stock at a public offering price of $18.50 per share, resulting in gross proceeds to Humanigen of approximately $92.5 million, before deducting underwriting discounts and commissions and offering expenses. The offering is expected to close on or about April 5, 2021. Humanigen also granted the underwriters a 30-day option to purchase up to an additional 750,000 shares at the public offering price, less underwriting discounts and commissions.

What was wrong with this? Or was the failure in one of the 8K prospectus filings?